Leveraging the Full Potential of Sensitive Circulating Tumor DNA Analyses

Abstract

Get full access to this article

View all access options for this article.

References

Aggarwal

, Thompson

, Black

, et al. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer. JAMA Oncology . 2019; 5(2):173–180.

Sartore-Bianchi

, Pietrantonio

, Lonardi

, et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nature Medicine . 2022; 28:1612–1618.

Cui

, Milner-Watts

, McVeigh

, et al. A pilot of blood-first diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer. Lung Cancer . 2022; 165:34–42.

Thompson

, Aggarwal

, Wong

, et al. OA16. 01 Plasma NGS At Time of Diagnostic Tissue Biopsy—Impact on Time to Treatment: Results From a Pilot Prospective Study. Journal of Thoracic Oncology . 2021; 16(10):S876.

Mok

, Wu

, Ahn

, et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. New England Journal of Medicine . 2017; 376(7):629–40.

Topham

, O'Callaghan

, Feilotter

, et al. Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer. Journal of Clinical Oncology . 2023; 41(3):485–496.